Acute Myeloid Leukemia Clinical Trials in Houston, Texas

52 studies are recruiting for acute myeloid leukemia in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

   Locations

   360 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

2. Study of REM-422 in Patients With AML or Higher Risk MDS

   The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   9 in total

   Run by

   Remix Therapeutics

   See if you can join NCT06297941 on ClinicalTrials.gov

3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   UT MD Anderson Cancer Center, Houston, Texas

   Locations

   747 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

4. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

   Locations

   187 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554393 on ClinicalTrials.gov

5. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

   Locations

   229 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06317649 on ClinicalTrials.gov

6. A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

   The primary purpose of Phase 1 is to characterize the safety and tolerability to identify the recommended dose (RD) of Debio 1562M for further development. The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   7 in total

   Run by

   Debiopharm International SA

   See if you can join NCT06969430 on ClinicalTrials.gov

7. A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

   Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center /ID# 279402, Houston, Texas

   Locations

   38 in total

   Run by

   AbbVie

   See if you can join NCT07581002 on ClinicalTrials.gov

8. CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

   This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   5 in total

   Run by

   CERo Therapeutics Holdings, Inc.

   See if you can join NCT06834282 on ClinicalTrials.gov

9. A Study of Revumenib and Mezigdomide in People With Leukemia

   The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   MD Anderson Cancer Center (Data Collection Only), Houston, Texas

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07356154 on ClinicalTrials.gov

10. Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

    This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M.D. Anderson Cancer Center, Department of Leukemia, Houston, Texas

    Locations

    2 in total

    Run by

    Montefiore Medical Center

    See if you can join NCT05986240 on ClinicalTrials.gov

11. PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

    This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Ext…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT02390635 on ClinicalTrials.gov

12. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

    Stage

    Phase 1

    Ages

    0 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    57 in total

    Run by

    Syndax Pharmaceuticals

    See if you can join NCT04065399 on ClinicalTrials.gov

13. Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

    This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs, such as decitabine, work i…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05010772 on ClinicalTrials.gov

14. A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

    A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    2 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06616636 on ClinicalTrials.gov

15. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    73 in total

    Run by

    Taiho Oncology, Inc.

    See if you can join NCT04256317 on ClinicalTrials.gov

16. Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

    This phase II trial studies how well venetoclax, cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated. Drugs used in chemotherapy, such as venetoclax, cladribine, and low dose cytarabine, work in different ways t…

    Stage

    Phase 2

    Ages

    50 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT03586609 on ClinicalTrials.gov

17. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

    Stage

    Phase 1

    Ages

    12 to 78

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    12 in total

    Run by

    Orca Biosystems, Inc.

    See if you can join NCT03802695 on ClinicalTrials.gov

18. Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

    This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed). Quizartinib may stop the growth of cancer cells by blocking some of the enzym…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT03661307 on ClinicalTrials.gov

19. A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

    Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia …

    Stage

    Phase 1

    Ages

    12 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05360160 on ClinicalTrials.gov

20. Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

    This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow…

    Stage

    Phase 1

    Ages

    1 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT03630991 on ClinicalTrials.gov

21. A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

    To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    4 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06284486 on ClinicalTrials.gov

22. Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

    The goal of this all-oral combination is to deliver safe and effective therapy for the largest portion of AML subtypes (NPM1mt, KMT2Ar, NUP98r ~ 40-45%).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06769490 on ClinicalTrials.gov

23. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

    This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

    Stage

    Phase 3

    Ages

    0 to 21

    Site

    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

    Locations

    206 in total

    Run by

    Children's Oncology Group

    See if you can join NCT04293562 on ClinicalTrials.gov

24. Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

    This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not r…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The Methodist Hospital Research Institute, Houston, Texas

    Locations

    64 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06824168 on ClinicalTrials.gov

25. Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

    This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocki…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Locations

    4 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT03471260 on ClinicalTrials.gov